|
- Alectinib - Wikipedia
Alectinib was granted an accelerated approval by the US Food and Drug Administration (FDA) in December 2015, to treat people with advanced ALK-positive NSCLC whose disease worsened after, or who could not tolerate, treatment with crizotinib (Xalkori)
- Alectinib: Uses, Dosage, Side Effects, Warnings - Drugs. com
Alectinib (Alecensa) is a type of cancer medication used to treat non-small cell lung cancer (NSCLC) in people who have an error in their anaplastic lymphoma kinase (ALK) gene
- Alectinib (oral route) - Side effects dosage
Alectinib is used to treat non-small cell lung cancer (NSCLC) that has spread or to help prevent NSCLC from coming back after the tumor has been removed by surgery in patients whose tumors have an abnormal anaplastic lymphoma kinase (ALK) gene
- Treatment Option for ALK+ NSCLC
Visit the official patient website for ALECENSA® (alectinib) See full safety for more information
- Alectinib: MedlinePlus Drug Information
Alectinib is used to treat a certain type of non-small-cell lung cancer (NSCLC) that has spread to other parts of the body Alectinib is in a class of medications called kinase inhibitors
- FDA Approves Alectinib for ALK-Positive Lung Cancer
Alectinib targets cancer cells that have specific changes, called rearrangements, in the ALK gene The drug has been shown to increase how long people with ALK-positive metastatic NSCLC live and has become a mainstay for treatment of people with this form of lung cancer
- Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK -positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
- Alecensa (alectinib): Uses, Side Effects, Interactions . . . - WebMD
Alecensa (alectinib) is commonly used for treating certain types of non-small cell lung cancer (NSCLC) It is used to prevent NSCLC from coming back after surgery to remove the tumor
|
|
|